<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang L</submitter><funding>Agency for Healthcare Research and Quality</funding><funding>NIDA NIH HHS</funding><funding>Foundation for the National Institutes of Health</funding><funding>Health Resources and Services Administration</funding><funding>National Institutes of Health</funding><funding>National Institute on Drug Abuse</funding><funding>Simon Fraser University</funding><pagination>e531-e539</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6693664</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(8)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Accurately estimating HIV disease progression and retention on antiretroviral therapy (ART) can help inform interventions to control HIV microepidemics and mathematical models used to inform health-resource allocation decisions. Our objective was to estimate the monthly probabilities of on-ART CD4 T-cell count progression, mortality, ART dropout, and ART reinitiation using a continuous-time multistate Markov model. We also aimed to validate health-state transition probability estimates to ensure they accurately reproduced the regional HIV microepidemics across the USA.&lt;h4>Methods&lt;/h4>In our modelling study, we considered a cohort of patients from the HIV Research Network, a consortium of 17 adult and paediatric HIV-care providers located in the northeastern (n=8), southe</pubmed_abstract><journal>The lancet. HIV</journal><pubmed_title>Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study.</pubmed_title><pmcid>PMC6693664</pmcid><funding_grant_id>R01 DA041747</funding_grant_id><funding_grant_id>HHSA290201100007C</funding_grant_id><funding_grant_id>R01DA041747-02S1</funding_grant_id><funding_grant_id>HHSH250201600009C</funding_grant_id><pubmed_authors>Gebo KA</pubmed_authors><pubmed_authors>Korthuis PT</pubmed_authors><pubmed_authors>Mathews WC</pubmed_authors><pubmed_authors>Mayer K</pubmed_authors><pubmed_authors>Diaz-Reyes R</pubmed_authors><pubmed_authors>Agwu A</pubmed_authors><pubmed_authors>Krebs E</pubmed_authors><pubmed_authors>Gaur A</pubmed_authors><pubmed_authors>Keruly J</pubmed_authors><pubmed_authors>Voss C</pubmed_authors><pubmed_authors>Wang L</pubmed_authors><pubmed_authors>Hellinger F</pubmed_authors><pubmed_authors>Beil R</pubmed_authors><pubmed_authors>Urbina A</pubmed_authors><pubmed_authors>Valenti W</pubmed_authors><pubmed_authors>Rutstein R</pubmed_authors><pubmed_authors>Moore RD</pubmed_authors><pubmed_authors>Aberg JA</pubmed_authors><pubmed_authors>Boswell S</pubmed_authors><pubmed_authors>Akbar M</pubmed_authors><pubmed_authors>Nijhawan A</pubmed_authors><pubmed_authors>Somboonwit C</pubmed_authors><pubmed_authors>Baranoski A</pubmed_authors><pubmed_authors>Felsen U</pubmed_authors><pubmed_authors>Min JE</pubmed_authors><pubmed_authors>Collins C</pubmed_authors><pubmed_authors>Fleishman J</pubmed_authors><pubmed_authors>Mills R</pubmed_authors><pubmed_authors>Edelstein H</pubmed_authors><pubmed_authors>Nosyk B</pubmed_authors><pubmed_authors>HIV Research Network</pubmed_authors><pubmed_authors>Allen S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study.</name><description>&lt;h4>Background&lt;/h4>Accurately estimating HIV disease progression and retention on antiretroviral therapy (ART) can help inform interventions to control HIV microepidemics and mathematical models used to inform health-resource allocation decisions. Our objective was to estimate the monthly probabilities of on-ART CD4 T-cell count progression, mortality, ART dropout, and ART reinitiation using a continuous-time multistate Markov model. We also aimed to validate health-state transition probability estimates to ensure they accurately reproduced the regional HIV microepidemics across the USA.&lt;h4>Methods&lt;/h4>In our modelling study, we considered a cohort of patients from the HIV Research Network, a consortium of 17 adult and paediatric HIV-care providers located in the northeastern (n=8), southe</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Aug</publication><modification>2025-04-29T10:31:16.136Z</modification><creation>2020-10-04T07:16:39Z</creation></dates><accession>S-EPMC6693664</accession><cross_references><pubmed>31303557</pubmed><doi>10.1016/S2352-3018(19)30148-1</doi><doi>10.1016/s2352-3018(19)30148-1</doi></cross_references></HashMap>